Global News Report : Acute Myeloid Leukemia (AML) Therapeutics Market – Epidemiology Analysis, Therapy, Development
The global acute myeloid leukemia therapeutics market is expected to witness notable growth, in the coming year due to increase in the new innovative and targeted drug delivery system. Various factors such as rising awareness regarding cancer treatments, increasing demand for safe and successful medications, rising incidence of cancer and technological advancements have been driving the growth of the global acute myeloid leukemia therapeutics market. Apart from this, various regulatory bodies are supporting the growth of the global market with funding, designations and grants, thereby accelerating the drug development process.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=acute-myeloid-leukemia-therapeutics-market
According to National Cancer Institute, a part of the U.S. National Institutes of Health, acute myeloid leukemia is a type of cancer that affects the blood and bone marrow. Acute myeloid leukemia is characterized by overproduction of immature white blood cells, myeloblasts or leukemic blasts. These cells crowd the bone marrow, preventing it from making normal blood cells. They can also spill out into the blood stream and circulate around the body. Due to their immaturity, these cells are unable to prevent or fight infections.
The pipeline of acute myeloid leukemia contains Durvalumab, a Phase II drug candidate of MedImmune. It is a fully human monoclonal antibody, which helps to overcome the immunosuppressive effects of B7-H1 on T-cells. Takeda Pharmaceutical Company Limited is developing a Phase II drug candidate, Alisertib, for the treatment of acute myeloid leukemia. It is an orally active, small-molecule inhibitor of the aurora A kinase. The aurora family of protein kinases is involved in the regulation of cell growth and proliferation, particularly in chromosome segregation and cytokinesis.
Download Report Sample at: https://www.psmarketresearch.com/market-analysis/acute-myeloid-leukemia-therapeutics-market/report-sample
Among marketed drugs, Decitabine is being co-developed by Eisai & Co., Ltd. and Johnson & Johnson. It is an intravenously administered DNA methylation. It is a deoxycytidine and cytarabine derivative, originated by SuperGen, Inc. The compound is available in Europe for acute myeloid leukemia. The product is also under regulatory review in China for Myelodysplastic syndromes and acute myeloid leukemia.
Many pharmaceutical companies are partnering with each other for research and development of acute myeloid leukemia. In December 2015, Massachusetts General Hospital, entered into a collaboration with Takeda to initiate a phase II trial to evaluate the efficacy of alisertib in combination with 7+3 induction chemotherapy, involving cytarabine and concurrent idarubicin or daunorubicin in patients with newly diagnosed high-risk acute myeloid leukemia. The open-label trial enrolled 39 patients in the U.S.
Some of the key players operating in the acute myeloid leukemia therapeutics market include Celgene Corporation, Eisai Co. Ltd., Bristol-Myers Squibb, Novartis AG, F. Hoffman La Roche AG, Genmab A/S, GlaxoSmithKline plc, and Takeda Pharmaceutical Company Limited.
About P&S Intelligence
P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Toll-free: +1-888-778-7886 (USA/Canada)
Email: [email protected]